Fig. 2.

Knockdown of oncogenic KRAS inhibits the expression of AATs, AA uptake, and mTOR activation in CRC cells. (A) Western blot images show the impact of knockdown of oncogenic KRAS on the protein expression of AATs (SLC7A5/LAT1, SLC1A5/ASCT2, and SLC38A2/SNAT2), KRAS, pan‐RAS, total‐MEK1/2, phospho‐MEK1/2, total‐S6, and phospho‐S6 ribosomal protein in CRC cell lines, SW480, SW620, and HCT116. β‐actin was used as protein loading control. All the experiments were performed three times independently, and the blots shown are representative of three independent replicates. (B, C) Impact of knockdown of KRAS on the l‐glutamine and l‐leucine uptake, measured by radioisotope‐based membrane transport assays. Data are presented as the mean ± SEM from three independent experiments (n = 3). Statistical comparisons were computed by one‐way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).